News Quantified

BTAI – bioxcel therapeutics, inc. (US:NASDAQ)

Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.

BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.

How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}